DL-031996-01

NRC FORM 37
(7-94)

OFFICIAL RECORD COPY

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 79

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Roanoke Memorial Hospitals Division of Nuclear Medicine	In accordance with letter dated March 7, 1996 3. License Number 45-01291-02 is amended in its entirety to read as follows:
2. Belleview and Jefferson Streets Roanoke, Virginia 24033	4. Expiration Date June 30, 2005
	5. Docket or Reference No. 030-03307

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (Not to exceed 10 Curies of I-131)
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed

9. Authorized use:

A. Medical use described in 10 CFR 35.100.
B. Medical use described in 10 CFR 35.200.
C. Medical use described in 10 CFR 35.300.
D. Medical use described in 10 CFR 35.400. Sealed cesium 137 brachytherapy sources may also be used for calibration of radiation detection equipment in accordance with procedures described in letters dated March 7, 1996 and March 15, 1996.
E. In vitro studies.

030053
9604040213 960319
PDR ADOCK 03003307
C PDR

License Number 45-01291-02

Docket or Reference Number 030-03307

Amendment No. 79

MATERIALS LICENSE SUPPLEMENTARY SHEET

CONDITIONS

10. A. Licensed material sha" be used only at Roanoke Memorial Hospital, Belleview & Jefferson Streets, Roanoke, Virginia

B. Licensed material specified in subitem 6.D. shall be stored at the Cancer Center of Southwest Virginia, Roanoke Memorial Hospital, 2013 Jefferson Street, S., Roanoke, Virginia.

11. Radiation Safety Officer: Joseph L. Surace

12. Authorized user(s):

A. Robert S. Creekmore, M.D. for medical uses designated in 10 CFR 35.100, 35.200, 35.300, 35.400 and 31.11.

B. James D. Rice, M.D. for medical uses designated in 10 CFR 35.100, 35.200, 35.300 and 31.11.

C. Marshall A. Wakat, M.D. for medical uses designated in 10 CFR 35.100, 35.200, 35.300, and 31.11.

D. J. Bruce Hauser, M.D. for medical uses designated in 10 CFR 35.100, 35.200, and 31.11. Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

E. Hugh J. Scruggs, M.D. for medical uses designated in 10 CFR 35.300 and 35.400.

F. Helen Maddux, M.D. for medical uses designated in 10 CFR 35.300 and 35.400.

G. Randolph Lewis Royster, M.D. for medical uses designated in 10 CFR 35.300 and 35.400.

H. Robert C. Heath, M.D. for medical uses specified in 10 CFR 35.300 and 35.400.

I. Michael J. Enright, M.D. for medical uses designated in 10 CFR 35.100, 35.200, 31,11 and Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

J. James G. Mullet, M.D. for medical uses designated in 10 CFR 35.100, 35.200, 31.11 and Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

K. Witold Brozyna, M.D. for medical uses designated in 10 CFR 35.100, 35.200 and 31.11.

L. Jeffrey S. Todd, M.D. for cardiac studies as identified in 10 CFR 35.200.

M. **Joe L. Surace for non-medical use associated with the performance and/or supervision of radiation safety duties and instrument calibration.**

13. Sealed sources containing licensed material shall not be opened by the licensee.

14. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

License Number 45-01291-02

Docket or Reference Number 030-03307

MATERIALS LICENSE
SUPPLEMENTARY SHEET

Amendment No. 79

CONDITIONS

Continued

15. The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facilities listed in Condition 10.A. pursuant to the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated November 30, 1994
    B. Fax transmission of letter dated June 8, 1995 [Clarifies that Dr. Todd has completed 500 hours of supervised work experience in compliance with 10 CFR 35.920(b)(2)]
    C. **Letter dated March 7, 1996 [Clarification of instrument calibration procedures and molybdenum concentration measurement techniques]**
    D. **Letter dated March 15, 1996 (FAX transmission) [Clarification of the scope of calibration procedures to include performing services for persons outside the licensee's organization on a non-profit basis]**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

Date MAR 19 1996

By Earl G. Wright
Region II, Division of Nuclear Materials Safety
101 Marietta Street, Suite 2900
Atlanta, GA 30323

N:\MLICENSE\45-01291A79